Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $220 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has reiterated a Neutral rating for Alnylam Pharmaceuticals, maintaining a price target of $220.
September 09, 2024 | 3:11 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald has reiterated a Neutral rating for Alnylam Pharmaceuticals, with a maintained price target of $220. This suggests that the analyst does not foresee significant short-term price movement.
The reiteration of a Neutral rating and maintenance of the $220 price target by Cantor Fitzgerald indicates that the analyst does not expect significant changes in Alnylam's stock price in the short term. This suggests stability rather than volatility.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100